Web19 uur geleden · HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer Web31 mrt. 2024 · HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that it completed the rolling submission of a New Drug Application …

HUTCHMED Highlights Presentations at American Association for …

WebHUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. It operates in... Web2 dagen geleden · HUTCHMED (China) Limited announced that Dr. Karen Jean Ferrante has informed the Company that she would retire from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2024 (“AGM”), and that she would not be seeking re-election at the AGM so that she could devote more time to her … myright bih

HUTCHMED (China) Limited kündigt Änderungen im Vorstand an

Web11 apr. 2024 · HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global … Web12 apr. 2024 · HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Web20 feb. 2024 · Inmagene and HUTCHMED announce today that the first participant, based in the United States, was dosed in a global Phase I trial of IMG-004. IMG-004 is a non-covalent, reversible, third-generation BTK … myrightchoicewellness.com